Co-occurring somatic mutations were found in 48% of MDS patients harboring TP53 mutations in Cluzeau et al.’s study, in which TET2, DNMT3A, JAK2, ASXL1, U2AF1, PPM1D, SF3B1, and NF1 account for the most frequently concurrent gene mutations, which is similar to Haase et al.’s results [15,60]. This evidence concerns the gene TP53 and myelodysplastic syndrome.